In the rapidly evolving landscape of biotherapeutics, the ability to precisely modulate gene expression within the gastrointestinal tract has become a cornerstone of modern drug development. As a leading Contract Research Organization (CRO) specializing in preclinical research, Creative Biolabs understands the complexities of the gut microbiome and the challenges of delivering fragile genetic payloads to this harsh environment. Our Lactococcus lactis-mediated RNAi delivery platform offers a sophisticated, bio-engineered solution to these hurdles, combining the natural safety of food-grade probiotics with the potent silencing capabilities of RNA interference.
Overview: The Power of Bio-Engineered Delivery
Traditional RNAi delivery often struggles with the high acidity of the stomach and the presence of degrading RNases in the intestinal lumen. Our service utilizes Lactococcus lactis, a Generally Recognized as Safe (GRAS) lactic acid bacterium, as a "living factory" and delivery vehicle. By engineering L. lactis to produce and release double-stranded RNA (dsRNA) or short hairpin RNA (shRNA) directly at the intestinal mucosa, we enable highly targeted gene knockdown in host cells or gut-dwelling pathogens. This approach is particularly effective for treating inflammatory bowel disease (IBD), metabolic disorders, and parasitic infections.
Service Portfolio: Comprehensive Preclinical Solutions
We provide a full-spectrum "end-to-end" service to transition your RNAi therapeutic from a sequence concept to a validated preclinical candidate.
Vector Design and Strain Engineering
-
Custom Expression Cassettes: Design of specialized plasmids for optimal dsRNA/shRNA expression.
-
Target Specificity: Bioinformatic screening to ensure high-affinity binding to target mRNA while minimizing off-target effects.
-
Biocontainment Strategies: Engineering of auxotrophic strains (e.g., thyA deletion) to ensure the bacteria cannot persist in the environment after excretion.
In Vitro Validation
-
Expression Profiling: Quantifying RNA production within the L. lactis carrier using RT-qPCR.
-
Cell Culture Models: Testing the delivery efficiency and gene-silencing potency in intestinal epithelial cell lines (e.g., Caco-2, HT-29).
In Vivo Efficacy and Safety
-
Animal Model Development: Utilizing DSS-induced colitis models, obesity models, or parasitic challenge models to test therapeutic outcomes.
-
Biodistribution Studies: Tracking the transit and localization of the engineered L. lactis within the GI tract.
-
Immunogenicity Assessment: Monitoring host cytokine profiles (IL-10, TNF-α, IFN-γ) to ensure a favorable safety profile.
Related Products for Preclinical Studies
To support your research, we offer a range of specialized products that complement our CRO services:
-
Engineered Control Strains: Standard L. lactis strains for baseline comparisons.
-
Fluorescently Labeled Strains: Fluorescent protein-expressing L. lactis for real-time visualization of bacterial localization in vivo.
Applications
The versatility of our L. lactis-mediated RNAi service allows it to be applied across various therapeutic areas:
-
Gastrointestinal Diseases: Silencing pro-inflammatory cytokines like TNF-α or IL-17 to treat Ulcerative Colitis and Crohn's disease.
-
Metabolic Disorders: Targeting intestinal genes involved in lipid absorption or glucose metabolism to combat obesity and Type 2 Diabetes.
-
Infectious Disease & Parasitology: Delivering RNAi to knock down essential genes in gut parasites (e.g., hookworms) or inhibiting viral replication at the mucosal surface.
-
Colorectal Cancer: Targeted delivery of shRNA to silence oncogenes (e.g., Aurora kinase A) within the intestinal epithelium.
Platform Advantages: Why Choose L. lactis?
Our platform stands out by addressing the three main barriers of oral gene therapy: Stability, Safety, and Site-Specificity.
Acid Resistance
L. lactis naturally survives the transit through the stomach, protecting the RNA payload within its cellular structure.
Non-Invasive & Non-Colonizing
Unlike some commensals, L. lactis typically transits the gut without permanent colonization, allowing for precise dosage control.
Inherent Adjuvant Properties
The peptidoglycan in the L. lactis cell wall can naturally interact with TLR2, subtly modulating the mucosal immune environment to support the therapeutic effect.
Cost-Effective Scalability
Compared to lipid nanoparticles (LNPs) or viral vectors, probiotic fermentation is significantly more affordable and easier to scale.
Over the last two decades, advances in synthetic biology have transformed these "friendly bacteria" into sophisticated therapeutic tools. By leveraging the natural "cross-talk" between the gut microbiota and the host immune system, L. lactis-mediated RNAi bypasses the systemic toxicity often associated with injectable gene therapies, providing a localized, mucosal-centric treatment paradigm. Partnering with us means gaining access to a team of dedicated microbiologists and geneticists who are committed to the success of your drug development journey. Whether you are in the early discovery phase or preparing for IND-enabling studies, our platform provides the precision and reliability required to move your project forward.
Would you like me to prepare a customized project proposal or a preliminary vector design strategy based on your specific target gene?
Frequently Asked Questions (FAQs)
How does the RNA get from the bacteria into the host cells?
There are two primary mechanisms. In some cases, the bacteria are internalized by "M cells" in the Peyer's patches. In others, the bacteria lyse or secrete vesicles containing the RNA, which are then taken up by adjacent epithelial cells.
Is there a risk of the engineered genes spreading to other gut bacteria?
We prioritize the use of non-mobilizable plasmids and genomic integration techniques to minimize the risk of horizontal gene transfer.
